The long-term safety and efficacy of (PROMACTA® (Eltrombopag) was evaluated in an open label phase III extension study (EXTEND STUDY) and this study demonstrated that Eltrombopag (PROMACTA®) given for up to two years appears to have consistent benefit in raising the platelet counts without any significant adverse events. A new paradigm has emerged with the availability of a new class of agents such as PROMACTA®, targeting platelet production. Additional trials are underway evaluating the role of this agent in chemotherapy induced thrombocytopenia as well as Myelodysplastic Syndromes and the results are eagerly awaited with renewed interest.
Month: January 2010
Oncoprescribe Blog Just added Synopsis/Clinical Relevance for ARZERRA for CLL
We’ve just completed a write up for ARZERRA for CLL, including a recap of the research presented at ASCO 2009 by Kipps, T. et al.
In a nutshell, here are the findings:
*The authors concluded that single agent therapy with Ofatumumab (ARZERRA®) acheives a high overall response rate and improves disease symptoms as well as hematologic parameters in heavily pretreated CLL patients presenting with double refractory and bulky Fludarabine orefractory disease, irrespective of prior therapy with Rituximab.*u
To view the entire Synopsis and Clinical Relevance, log on to www.oncoprescribe.com – if aren’t registered yet; the subscription is free.